Recombinant Human Interleukin-18 receptor accessory protein (IL18RAP)

What is IL18RAP and what is its role in immune signaling?

IL18RAP (Interleukin-18 receptor accessory protein) functions as the beta chain of the IL-18 receptor complex. It is an essential accessory protein required for IL-18 signaling through its specific cell surface receptor. The complete IL-18 receptor comprises two subunits: IL-18Rα (IL18R1) and IL-18Rβ (IL18RAP). While IL-18Rα alone exhibits weak affinity for IL-18 binding, the IL-18Rα/β complex demonstrates high affinity binding. This receptor complex is critical for IL-18-mediated activation of downstream signaling pathways that regulate innate and adaptive immune responses .

Where is IL18RAP expressed in normal human tissues?

IL18RAP expression has been detected in numerous tissues throughout the body. Principal sites of expression include lung, spleen, leukocytes, and colon . At the cellular level, single-cell RNA sequencing analysis reveals that IL18RAP is predominantly expressed in immune cells . In particular, IL18RAP is expressed in monocytes, macrophages, and other cells that respond to inflammatory signals. This widespread tissue distribution reflects the importance of IL18RAP in coordinating immune responses across multiple organ systems.

How does IL18RAP signaling affect cytokine production?

IL18RAP signaling significantly amplifies cytokine production following pattern recognition receptor (PRR) stimulation. When IL18RAP expression or function is reduced (through knockdown experiments or neutralizing antibodies), there is a dramatic decrease in both pro-inflammatory and anti-inflammatory cytokine secretion in response to PRR activation . Mechanistically, PRR stimulation triggers a caspase-1-dependent cleavage of pre-existing pro-IL-18, leading to autocrine IL-18 signaling. This autocrine loop, acting through IL18RAP, is critical for optimal PRR-induced MAPK, NF-κB, PI3K, and calcium signaling pathways, which collectively drive robust cytokine secretion .

What genetic polymorphisms in IL18RAP are associated with immune-mediated diseases?

The IL18RAP gene region contains several polymorphisms associated with multiple immune-mediated conditions. Most notably, the rs917997 polymorphism (particularly the AA genotype) has been linked to increased risk for inflammatory bowel disease (IBD) and celiac disease . Other conditions associated with IL18RAP polymorphisms include atopic dermatitis, leprosy, and type I diabetes . A gene cluster on human chromosome 2q containing both IL18R1 and IL18RAP has been associated with asthma in genome-wide association studies . These genetic associations highlight the central role of IL-18 signaling in regulating immune homeostasis.

What are the recommended methods for measuring IL18RAP expression in human samples?

To measure IL18RAP expression in human samples, researchers can employ several complementary approaches:

• mRNA quantification: Quantitative RT-PCR using primers that detect all three known IL18RAP isoforms provides a comprehensive assessment of gene expression. When designing primers, consider that three IL18RAP isoforms have been identified in human tissues .

• Protein detection: Surface IL18RAP protein can be measured by flow cytometry using specific anti-IL18RAP antibodies. Western blotting can also be used, though researchers should note that while the predicted molecular weight of recombinant human IL18RAP is 65.1 kDa, it typically migrates at 90-100 kDa on SDS-PAGE, likely due to post-translational modifications .

• Single-cell approaches: For high-resolution analysis, single-cell RNA sequencing can determine cell-specific expression patterns of IL18RAP within heterogeneous samples .

How can researchers effectively block IL18RAP signaling in experimental systems?

Multiple approaches can be used to inhibit IL18RAP signaling in experimental systems:

• Neutralizing antibodies: Anti-IL18RAP neutralizing antibodies can block the proposed autocrine IL-18 signaling loop. This approach has been shown to dramatically downregulate NOD2-induced proinflammatory and anti-inflammatory cytokine secretion .

• siRNA knockdown: Targeted siRNA can effectively reduce IL18RAP expression. When implementing this approach, researchers should verify knockdown efficiency and ensure that cell viability remains unaffected .

• Recombinant IL18RAP-Fc fusion proteins: Soluble IL18RAP-Fc fusion proteins can act as decoys to inhibit IL-18 signaling. In experimental systems, these constructs can inhibit IL-18 induced responses in cellular assays .

• CRISPR-Cas9 gene editing: For stable knockout models, CRISPR-Cas9 technology can be employed to eliminate IL18RAP expression.

What is the biological activity assay for recombinant human IL18RAP?

The biological activity of recombinant human IL18RAP can be assessed by its ability to inhibit IL-18 induced responses in appropriate cell models. A standard approach uses KG-1 cells in the presence of soluble IL-18Rα/Fc. The typical ED50 for this inhibitory effect is 2-6 μg/mL when used with 30 μg/mL of soluble IL-18Rα/Fc and 40 ng/mL of human IL-18 . When conducting this assay, researchers should include appropriate controls and ensure that the recombinant protein preparation has >90% purity as determined by SDS-PAGE with silver staining .

How does the rs917997 polymorphism in the IL18RAP region affect immune function?

The rs917997 polymorphism in the IL18RAP region leads to a significant loss of function through multiple mechanisms:

• Decreased receptor expression: This polymorphism results in reduced surface protein expression of IL18RAP, IL18R1, and IL1R1 .

• Impaired cytokine signaling: Due to the decreased receptor expression, cells from carriers of this polymorphism exhibit impaired autocrine IL-18 and IL-1 signaling .

• Reduced PRR-induced cytokine secretion: Macrophages from individuals with the risk-associated AA genotype show diminished cytokine secretion in response to PRR stimulation, even at high doses of stimulants like MDP (muramyl dipeptide) .

• Broad PRR pathway effects: The functional consequences extend across multiple PRR-initiated pathways, including NOD2, NOD1, TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9 signaling .

This suggests that individuals carrying this polymorphism may have altered immune responses to microbial signals, potentially contributing to disease susceptibility.

What is the evidence for IL18RAP involvement in autoimmune diseases?

Evidence for IL18RAP involvement in autoimmune diseases comes from multiple lines of investigation:

• Genetic associations: IL18RAP polymorphisms are strongly associated with multiple autoimmune conditions, including IBD, celiac disease, type I diabetes, and atopic dermatitis .

• Expression studies: In systemic lupus erythematosus (SLE), IL18RAP expression is significantly elevated in patients with lupus nephritis compared to non-nephritic lupus patients .

• Clinical correlations: IL18RAP expression negatively correlates with complement C3 levels and positively correlates with SLEDAI-2K scores in SLE patients, indicating a relationship with disease activity .

• Mechanistic studies: IL18RAP expression is regulated by type I interferon in neutrophils, providing a link to the interferon signature seen in many autoimmune conditions .

These findings collectively suggest that IL18RAP plays an important role in autoimmune disease pathogenesis, potentially through dysregulation of immune responses to microbial components.

What is the potential role of IL18RAP as a biomarker in cancer?

IL18RAP has emerging potential as a biomarker in several cancer contexts:

• Prognostic indicator: Gene set enrichment analysis (GSEA) has revealed that IL18RAP is related to various immunological processes important in cancer, including positive regulation of interferon gamma production and NK cell-mediated immunity .

• Predictive biomarker: Both human and mouse cancer cohort studies indicate that IL18RAP expression levels can predict immunotherapy response, suggesting potential utility in identifying patients who might benefit from immune checkpoint inhibitors .

• Cell type-specific effects: Single-cell RNA sequencing analysis has detected that IL18RAP is mainly expressed in tumor-infiltrating immune cells. HALLMARK analysis confirmed that IFN-γ gene set expression was upregulated in CD8+ exhausted T cells (CD8Tex), connecting IL18RAP to T cell function in the tumor microenvironment .

• Therapeutic target potential: Given its role in immune regulation, IL18RAP may represent a potential immunotherapeutic target in cancer treatment strategies .

How can IL18RAP be targeted to enhance anti-tumor immunity?

Several strategies are being explored to target IL18RAP for enhanced anti-tumor immunity:

• Engineered IL-18 cytokines: Researchers have developed engineered IL-18 heterodimeric Fc-fusions with improved pharmacokinetics and reduced sensitivity to the natural inhibitor IL18BP. These modified cytokines demonstrate robust inflammatory activity in vivo and could potentially enhance IL18RAP-mediated signaling in tumor-infiltrating lymphocytes .

• Combination approaches: Preclinical studies with recombinant IL-18 have demonstrated impressive synergy with both immune checkpoint inhibitors and CAR-T therapy, suggesting that targeting the IL-18/IL18RAP pathway could enhance existing immunotherapies .

• Overcoming negative regulation: IL-18 participates in a negative feedback loop with a high-affinity natural inhibitor, IL-18 binding protein (IL18BP). Engineering IL-18 variants that resist IL18BP inhibition while maintaining IL18RAP signaling could potentially improve therapeutic efficacy .

• Cell-specific delivery: Targeted delivery of IL-18 or IL18RAP agonists to tumor sites could potentially enhance local immune activation while minimizing systemic side effects.

What experimental models are appropriate for studying IL18RAP function in inflammatory diseases?

Several experimental models have proven valuable for studying IL18RAP function in inflammatory contexts:

• Primary human monocyte-derived macrophages (MDMs): These cells provide an excellent system for studying IL18RAP signaling in response to microbial components. MDMs express IL18RAP and respond robustly to PRR stimulation, making them suitable for mechanistic studies of IL18RAP in innate immunity .

• Neutrophil models: Given the regulation of IL18RAP by type I interferons in neutrophils, these cells offer insights into how IL18RAP contributes to neutrophil function in inflammatory diseases like SLE .

• Genetically stratified human samples: Comparing cells from individuals with different IL18RAP genotypes (e.g., carriers vs. non-carriers of the rs917997 risk allele) provides a powerful approach to understanding the functional consequences of genetic variation .

• Mouse models with targeted IL18RAP manipulation: Genetic knockout or conditional deletion of IL18RAP in mice can help define its role in specific disease models, such as experimental colitis, asthma, or cancer.

• Ex vivo culture systems: Treating healthy immune cells with patient sera (e.g., SLE sera with high or low interferon activity) can reveal how disease-associated factors regulate IL18RAP expression .

How do the three known isoforms of human IL18RAP differ in function and expression patterns?

Three IL18RAP isoforms have been identified in human tissues, with distinct characteristics:

• Expression patterns: All three isoforms show increased expression following NOD2 stimulation, with peak expression at approximately 2 hours post-stimulation .

• Tissue distribution: The different isoforms may show tissue-specific expression patterns, though comprehensive mapping across tissues remains to be completed.

• Functional differences: While all isoforms contribute to IL-18 signaling, potential differences in signaling efficiency, ligand binding affinity, or downstream pathway activation require further investigation.

• Regulation: The transcriptional and post-transcriptional mechanisms that control the relative abundance of each isoform may differ depending on cell type and stimulation conditions.

For comprehensive analysis, researchers should consider using primers that detect all three IL18RAP isoforms, as well as isoform-specific primers to distinguish between them .

What are the implications of IL18RAP in the design of therapies for immune-mediated diseases?

The role of IL18RAP in immune regulation has important implications for therapeutic development:

• Caution in IL-18 pathway targeting: Research suggests that maintaining or enhancing, rather than inhibiting, IL-18 signaling might be more efficacious for certain diseases. This is based on observations that diminished IL18RAP function is associated with increased risk for several immune-mediated conditions .

• Precision medicine approaches: Given the impact of IL18RAP polymorphisms on disease risk, genotyping patients for relevant IL18RAP variants could help stratify populations for targeted therapies.

• Balance in pathway modulation: IL-18 can have both protective and detrimental roles in different contexts. For example, diminished IL-18 induction exacerbates experimental colitis, but IL-18 administration can induce murine colitis in other settings . Therefore, therapeutic approaches need to consider this balance.

• Consideration of related pathways: The IL18RAP region polymorphism affects not only IL-18 but also IL-1 pathway signaling, suggesting that comprehensive targeting of related inflammatory pathways may be necessary for therapeutic efficacy .

What are the critical quality control parameters for recombinant IL18RAP protein?

When working with recombinant human IL18RAP protein, several quality control parameters should be assessed:

• Purity: Recombinant IL18RAP should have >90% purity as determined by SDS-PAGE and silver staining .

• Endotoxin levels: Endotoxin contamination should be <1.0 EU/μg as determined by the LAL (Limulus Amebocyte Lysate) method to prevent non-specific activation of immune cells .

• Molecular weight verification: While the predicted molecular weight of recombinant human IL18RAP is 65.1 kDa, it typically migrates at 90-100 kDa on SDS-PAGE due to post-translational modifications .

• Biological activity: Functional testing should confirm the protein's ability to inhibit IL-18 induced responses (e.g., in KG-1 cells) with an expected ED50 of 2-6 μg/mL under standardized conditions .

• Stability assessment: Properly lyophilized protein should maintain activity for six to twelve months when stored desiccated at -20°C to -70°C .

How can researchers address variability in IL18RAP expression studies across different cell types?

Variability in IL18RAP expression studies can be addressed through several methodological approaches:

• Standardized isolation protocols: Use consistent cell isolation methods to minimize technical variability, particularly for primary cells like monocytes, macrophages, and neutrophils.

• Time-course experiments: As IL18RAP expression can change rapidly after stimulation (peaking at 6 hours for protein and 2 hours for mRNA after NOD2 stimulation) , detailed time-course experiments are essential to capture dynamic expression changes.

• Multiple detection methods: Combine mRNA and protein detection methods (qPCR, flow cytometry, Western blot) to provide complementary data on IL18RAP expression.

• Appropriate housekeeping genes: Validate stable reference genes for each cell type and experimental condition to ensure accurate normalization of qPCR data.

• Single-cell approaches: When working with heterogeneous populations, consider single-cell RNA sequencing to resolve cell type-specific expression patterns .

What strategies can improve the reproducibility of IL18RAP functional assays?

To enhance reproducibility in IL18RAP functional assays, researchers should consider:

• Careful cell source selection: Primary cells from different donors can exhibit significant variability. Consider using pooled donors or well-characterized cell lines for initial studies.

• Titration of reagents: Establish dose-response relationships for key reagents, including recombinant proteins, neutralizing antibodies, and stimulants like MDP (muramyl dipeptide) .

• Positive and negative controls: Include appropriate controls in each experiment, such as isotype control antibodies for neutralization experiments and non-targeting siRNA for knockdown studies .

• Verification of knockdown/blocking efficiency: When inhibiting IL18RAP, confirm the degree of knockdown or neutralization achieved before interpreting downstream functional effects.

• Multiple readouts: Assess multiple functional outcomes (e.g., different cytokines, signaling pathways) to build a comprehensive picture of IL18RAP's role in your experimental system .